-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Sumitomo Pharmaceuticals and Exscientia
Sumitomo Pharmaceuticals and Exscientia
On January 30, 2020, Dainippon Sumitomo Pharmaceuticals and Exscientia Ltd.
On January 30, 2020, Dainippon Sumitomo Pharmaceuticals and Exscientia Ltd.
Sumitomo Pharmaceuticals has made great achievements in the field of central nervous system diseases (CNS).
Sumitomo Pharmaceuticals has made great achievements in the field of central nervous system diseases (CNS).
In this collaboration, Sumitomo Pharmaceuticals provides knowledge and experience in monoamine G protein-coupled receptor drug discovery.
In this collaboration, Sumitomo Pharmaceuticals provides knowledge and experience in monoamine G protein-coupled receptor drug discovery.
02Exscientia and Evotec
02Exscientia and Evotec
On April 9, 2021, Exscientia announced that the first tumor immune small molecule EXS21546 designed by the company's AI platform will soon enter the human clinical trial (FIH).
On April 9, 2021, Exscientia announced that the first tumor immune small molecule EXS21546 designed by the company's AI platform will soon enter the human clinical trial (FIH).
The A2a receptor receptor is one of the four adenosine receptors (A1, A2A, A2B and A3).
The A2a receptor receptor is one of the four adenosine receptors (A1, A2A, A2B and A3).
03 Ice Island Stone Biology
03 Ice Island Stone Biology
Among the domestic AI pharmaceutical companies, Accutar Biotechnology was established in 2015.
Among the domestic AI pharmaceutical companies, Accutar Biotechnology was established in 2015.
The founder is Dr.
The founder is Dr.
The company said to the outside that AccutarBio has built a full-link AI pharmaceutical platform, which has opened up all aspects of preclinical research and development of small molecule drugs, including virtual screening, drug attribute prediction, chemical reverse synthesis, drug optimization, and new use of old drugs.
The company said to the outside that AccutarBio has built a full-link AI pharmaceutical platform, which has opened up all aspects of preclinical research and development of small molecule drugs, including virtual screening, drug attribute prediction, chemical reverse synthesis, drug optimization, and new use of old drugs.
At present, AccutarBio has established a pipeline of more than 10 new drug candidates, covering first-in-class and best-in-class drug targets.
Two of the pipelines (breast cancer and prostate cancer) are expected to enter clinical trials in the United States in the second half of 2021, and the other two pipelines will undergo clinical IND declarations in the United States in early 2022.
At present, AccutarBio has established a pipeline of more than 10 new drug candidates, covering first-in-class and best-in-class drug targets.
Two of the pipelines (breast cancer and prostate cancer) are expected to enter clinical trials in the United States in the second half of 2021, and the other two pipelines will undergo clinical IND declarations in the United States in early 2022.
04AI Pharmaceutical Ecology
04AI Pharmaceutical Ecology
According to incomplete statistics from the Yaorong Cloud database, the leading foreign AI pharmaceutical platforms include:
According to incomplete statistics from the Yaorong Cloud database, the leading foreign AI pharmaceutical platforms include:
Schrdinger, Exscientia, AbCellera Biologics, Recursion Pharmaceuticals, Atomwise, Benevolent, Insilico, Silicon Health (recently acquired), Insitro, Cyclica, etc.
Schrdinger, Exscientia, AbCellera Biologics, Recursion Pharmaceuticals, Atomwise, Benevolent, Insilico, Silicon Health (recently acquired), Insitro, Cyclica, etc.
Domestic companies that use AI to engage in related development in the field of drug research and development include: Prolion Biology, Wangshi Wisdom, Jingtai Technology, Yudao Biology, Fermion, Suikun Intelligent, Mingjun, METiS, Xingkangyuan Biology, Orri Pharmaceutical , Mizuki Future, Kehui Zhiyao, Wuhan Zhihua Technology, Xinhe Biology, Yunshen Zhiyao, Baitu Shengke, Almai Biology, Kangmai Disen, Infineon Intelligent Medicine, Yiyao Technology, Zhiyao Technology, Sai Ke Technology, Nanjing Shuangyun Biology, Deep-Depth Zhiyao, Xingyao Technology, Fendi Technology, Chuangteng Technology and so on.
Domestic companies that use AI to engage in related development in the field of drug research and development include: Prolion Biology, Wangshi Wisdom, Jingtai Technology, Yudao Biology, Fermion, Suikun Intelligent, Mingjun, METiS, Xingkangyuan Biology, Orri Pharmaceutical , Mizuki Future, Kehui Zhiyao, Wuhan Zhihua Technology, Xinhe Biology, Yunshen Zhiyao, Baitu Shengke, Almai Biology, Kangmai Disen, Infineon Intelligent Medicine, Yiyao Technology, Zhiyao Technology, Sai Ke Technology, Nanjing Shuangyun Biology, Deep-Depth Zhiyao, Xingyao Technology, Fendi Technology, Chuangteng Technology and so on.
